Metastatic prostate cancer (with prostate-specific antigen of 9996) presenting as obstructive jaundice

American Journal of the Medical Sciences

Volumn 319, Issue 2, 2000, Pages 118-122

  Cole, Ariel ^a   Mendelblatt, David ^a   Aguayo, Jose ^a   Mathew, Anitha ^a   Martin, Elena ^a   Vesely, David L ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bicalutamide; Leuprolide; Obstructive jaundice; Prostate cancer; Prostate specific antigen

Indexed keywords

ALKALINE PHOSPHATASE; BICALUTAMIDE; BILIRUBIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE PAIN; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LYMPHADENOPATHY; MALE; METASTASIS; OBSTRUCTIVE JAUNDICE; PELVIS PAIN SYNDROME; PROSTATE CANCER;

EID: 0034036486     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9629(15)40699-8     Document Type: Article

References (14)

1. Ben-Ishay D, Slavin S, Levij IS, et al. Obstructive jaundice associated with carcinoma of the prostate. Isr J Med Sci 1975;11:838-44.
2. Bloch WE, Block NL. Metastatic prostate cancer presenting as obstructive jaundice. Urology 1992;40:456-7.
3. Mannion RA, Johnson M. Case report: accumulation of 99 m Tc-hydroxymethylene diphosphonate by liver metastases of prostate adenocarcinoma. Clin Radiol 1993;47:209-10.
4. Lombardi A, Ferrazza P, Castaldi F, et al. Necrosi epatica acuta in pazlente sottoposto a terapia con cipoterone acetato. Giornale di Chirurgia 1998;19:161-163.
5. Moller S, Iverson P, Franzmann MB. Flutamide-induced liver failure. J Hepatology 1990;10:342-9.
6. Rosman AS, Frissora-Rodeo C, Marshall AT, et al. Cholestatic hepatitis following flutamide. Dig Dis Sci 1993;38: 1756-879.
7. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urology 1996;155:209-12.
8. Lee HW, Chung JP, Leek S, et al. A case of flutamide-induced acute cholestatic hepatitis - a case report. Yonsei Med J 1996;37:225-9.
9. Lin DW, Noteboom JL, Blumenstein BA, et al. Serum percent free prostate specific antigen in metastatic prostate cancer. Urology 1998;52:366-71.
10. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Eng J Med 1987;317:909-16.
11. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume, and benign hyperplasia. J Urology 1990;143:747-52.
12. Frazier HA, Robertson JE, Humphrey PA, et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urology 1993;149: 516-518.
13. Leuprolide acetate. In: McEnvoy GK, editor. American Hospital Formulary Service drug information 98 (1). Bethesda: American Society of Health-System Pharmacists; 1998. p. 873-81.
14. Bicalutamide. In: McEnvoy GK, editor. American Hospital Formulary Service drug information 98 (1). Bethesda: American Society of Health-System Pharmacists; 1998. p. 742-3.